Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Investor Presentation (June 2025)
21 slides from Neuroscientific Biopharmaceuticals's investor presentation, Jun 30, 2025
Slide 1: NeuroScientific Secures Breakthrough Stem Cell Tech in Strategic Acquisition
ASXNSB For personal use only NeuroScientific Secures Breakthrough Stem Cell Tech in Strategic Acquisition June 2025 1 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based Forward Looking Statements For personal use only on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not
Slide 3: Crohn's Breakthrough? NSB Pushes Stem Cell Treatment Globally
ASXNSB For personal use only Crohn’s Breakthrough? NSB Pushes Stem Cell Treatment Globally NSB’s Focus on Neuroimmune Disorders and Biomedical Innovation NSB is an ASX-listed biotechnology company dedicated to the research and development of biomedical products targeting neurodegenerative conditions
Slide 4: Investor Overview
Investor Overview For personal use only CORPORATE SHARE INFORMATION LIVE SHARE PRICE ASX Announcement AS AT 27 JUNE 2025 16 April 2025 AS AT 27 JUNE 2025 ‘Neuroscientific to Acquire Leading Stem Cell Technology SHARE PRICE A$0.080 MARKET CAPITALISATION A$26.5 million 16 April 2025 CAPITAL STRUCTURE &
Slide 5: Board
Board For personal use only Dr Uvarov has significant experience in the healthcare industry Rob is a lawyer with over 35 years’ experience in ROB MCKENZIE DR ANTON UVAROV with a particular focus on neuroscience. Dr Uvarov started his corporate and commercial transactions, restructuring LL.B; B.Juris,
Slide 6: What are Mesenchymal Stem Cells (MSC)
ASXNSB For personal use only What are Mesenchymal Stem Cells (MSC) MSC are adult stem cells traditionally harvested from bone marrow. MSC can also be How does Stem Cell isolated from other tissues. technology work? Stem cells are often called the “body's MSC building blocks”, as they can potentially
Slide 7: Introducing StemSmart
Introducing StemSmartTM StemSmartTM early indications from the Phase 2 trial in refractory Crohn’s disease For personal use only suggest StemSmartTM MSC is potent, efficacious and safe1 StemSmart TM High quality product manufactured under StemSmartTM methodology StemSmartTM is a global patented techn
Slide 8: Cell therapy for Serious Inflammatory Immune Disorders
Cell therapy for Serious Inflammatory Immune Disorders For personal use only Mesenchymal Stem Cells (MSC) have a strong safety profile StemSmart TM MSC require an inflammatory environment to be activated for clinical effect StemSmartTM MSC are primed to respond to inflammation o MSC work most effectivel
Slide 9: What is Crohn's Disease?
ASXNSB Stem Cell Technology for For personal use only What is Crohn’s Disease? StemSmart TM Refractory Crohn’s Refractory Crohn’s (life threatening) o Life-long chronic inflammation of the gut Unresponsive to conventional therapies (Antibiotics/Steroids/Biologics) o Incurable affecting more than 1 mi
Slide 10: FDA Approval: Industry News
ASXNSB Industry News For personal use only United States FDA recently approved the first mesenchymal stromal cell1 FDA Approval United States FDA recently approved the first mesenchymal stromal cell (MSC) therapy (Mesoblast ASX Announcement 19.12.2024 (ASX: MSB - MSB market capitalisation as at 18 Jun
Slide 11: Special Access Program
Special Access Program1 Has now commenced For personal use only Crohn’s Fistulas o Commenced in June 20252 StemSmart TM o <12 patients Treatment of patients with Crohn’s o Non healing fistulas Fistulas on compassionate grounds o Administration of StemSmartTM at weekly intervals, for 4 weeks (SAS) o E
Slide 12: StemSmart MSC isn't just for Crohn's Disease
StemsmartTM MSC isn’t just for Crohn’s Disease For personal use only Clinical Indication Description Trials/studies reported using StemsmartTM MSC 1 Refractory GvHD o GVHD is a common complication of allogeneic (donor) bone marrow transplant o Positive and life-saving clinical results of StemSmartTM
Slide 13: Key Conditions Focus & Market Size
Key Conditions Focus & Market Size (StemSmartTM MSC addressable markets) Forecast Increase Global Market in Market For personal use only ● Need for more effective treatments with less side effects US$13.8 billion Crohn’s Disease ● Require additional treatment option for patients who have By 20261 53
Slide 14: Key Corporate Factors
ASXNSB Key Corporate Factors For personal use only Global Crohn’s Patented SAS Fistulising Crohn’s Market Situation Technology Program Initiated Diversification Results pending The power of StemSmart StemSmart TM StemSmart holds significant Following the successful Phase 2 trial in Diversifying resear
Slide 15: For further information, please contact
ASXNSB For personal use only For further information, please contact: Dr Anton Uvarov Founding Non-Executive Director +61 8 6268 2641 au@neuroscientific.com Mr Chris Achurch Company Secretary +61 8 6268 2641 [email protected] 15 15
Slide 16: Annexures
For personal use only Annexures ASXNSB 16 16
Slide 17: Annexure: Phase 2 Trial in Biologic Refractory Crohn's Disease
Annexure 1 Clinical Trial A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn’s Disease Condition Crohn’s Disease, biologic refractory For personal use only Drug Human, allogeneic, bone-marrow derived, mesenchymal
Slide 18: Annexure: Phase 1 Study in Steroid Refractory GVHD
Annexure 2 Clinical Trial A phase I study to evaluate the potential of mesenchymal stromal cells to treat steroid refractory graft versus host disease (both acute and chronic) after bone marrow transplantation For personal use only Condition Acute and chronic steroid-refractory graft versus host dis
Slide 19: Annexure: Compassionate Use in Refractory GVHD
Annexure 3 Clinical Study Compassionate use of mesenchymal stromal cells in refractory graft versus host disease after bone marrow transplantation Condition Acute and chronic steroid-refractory graft versus host disease following allogeneic bone marrow transplant For personal use only Drug Human, al
Slide 20: Annexure: Phase 2 Trial in De Novo Acute GVHD
Annexure 4 Clinical Trial A phase II trial of standard of care treatment versus mesenchymal stromal cells therapy together with standard of care treatment for the treatment of de novo acute graft versus host disease following allogeneic bone marrow transplantation For personal use only Condition New
Slide 21: Annexure (Cont.): Outcome Summary
Annexure 4 (Cont.) Outcome Summary Early results do not support the use of MSC in addition to corticosteroids at first diagnosis of acute GVHD. Study, which was planned to recruit 66 patients, was terminated early on grounds of futility. For personal use only Challenges of study: ● Recruitment was sl
NeuroScientific Biopharmaceuticals — Investor Presentation (June 2025) on 6ix